Randomized comparative trial of triflusal and aspirin following acute myocardial infarction

European Heart Journal

Volumn 21, Issue 6, 2000, Pages 457-465

  Cruz Fernandez J M ^a   Lopez Bescos L ^b   Garcia Dorado D ^c   Lopez Garcia Aranda V ^a   Cabades A ^d   Martin Jadraque L ^e   Velasco, J A ^f   Castro Beiras, A ^g   Torres, F ^h   Marfil, F ⁱ   Navarro, E ^j  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

ⁱ HOSPITAL TORRECÁRDENAS   (Spain)

^j HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

more..

Author keywords

Acute myocardial infarction; Aspirin; Cardiovascular events; Cerebrovascular events; Sequential trial; Triflusal

Indexed keywords

ACETYLSALICYLIC ACID; TRIFLUSAL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SALICYLATES; SPAIN; TREATMENT OUTCOME;

EID: 0342288676     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1874     Document Type: Article

References (26)

1. BMJ. 308:1994;81-106.
2. Lancet. ii:1988;349-360.
3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 330:1994;1287-1294.
4. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 35:1993;219-226.
5. N Engl J Med. 321:1989;129-135.
6. Hirsh Jy, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ. Aspirin and other platelet active drugs: the relationship between dose, effectiveness, and side-effects. Chest. 108:1995;S247-57.
7. Boysen G, Boss AH, Odum N, Olsen JS. Prolongation of bleeding time and inhibition of platelet aggregation by low dose acetylsalicylic acid in patients with cerebrovascular disease. Stroke. 15:1984;241-243.
8. de la Cruz JP, Villalobos MA, Garcia PJ. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharmacol. 47:1995;497-502.
9. Albors M, Castellarnau C, Vila L, Sola J, Rutllant ML. Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Rev Pharmacol Clin Exp. 4:1987;11-16.
10. de la Cruz JP, Mata JM, Sánchez de la Cuesta F. Triflusal versus aspirin on the inhibition of human platelet and vascular cyclooxygenase. Gen Pharmacol. 23:1992;297-300.
11. García-Rafanell J, Ramis J, Gómez L, Forn J. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther. 284:1986;155-165.
12. Fernández de Arriba A, Cavalcanti F, Miralles A. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol. 55:1999;753-760.
13. Bayón Y, Alonso A, Sánchez Crespo M. 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid are potent inhibitors of nuclear factor kB activation. Br J Pharmacol. 126:1999;1359-1366.
14. Sánchez de Miguel L, del Prado Sierra M, López Farré A. Comparative effects of triflusal and acetylsalicylic acid on nitric oxide generation by human neutrophils. Eur J Pharmacol. 343:1998;57-65.
15. Plaza L, López-Bescós L, Martín-Jadraque L. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicentre trial. Grupo de Estudio del Triflusal en la Angina Inestable. Cardiology. 82:1993;388-398.
16. Auteri A, Angaroni A, Borgatti E. Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs. placebo. Int J Clin Pharmacol Res. 15:1995;57-63.
17. Matías-Guiu L, Alvarez-Sabín J, Codina A. Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischaemic cerebrovascular disease. Long-term outcome of young stroke patients. Rev Neurol. 25:1997;1669-1672.
18. Smirne S, Ferini-Strambi L, Cucinotta D. Triflusal and prevention of cerebrovascular attacks: a double-blind clinical study vs ASA [abstract 53]. J Neurol. 241:1994;S130.
19. Putz P, Buyse H, Delvaux D. Triflusal versus acetylsalicylic acid: a double-blind study for the prophylaxis of deep vein thrombosis after hip surgery. Acta Chir Belg. 91:1991;269-276.
20. Monreal M, Lafoz E, Roca J. Platelet count, antiplatelet therapy and pulmonary embolism - a prospective study in patients with hip surgery. Thromb Haemost. 73:1995;380-385.
21. Masotti M, Tura A, Crexells C. Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty. J Int Med Res. 19:1991;414-418.
22. Guiteras P, Altamiras J, Aris A. Prevention of aorto-coronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomised, double-blind, placebo-controlled trial. Eur Heart J. 10:1989;159-167.
23. Whitehead J. The design and analysis of sequential clinical trials. 1992;Ellis Horwood, Chichester.
24. Whitehead J, Brunier H. PEST 2.0 Operating Manual. 1989;Reading University, Reading.
25. Brunier H, Whitehead J. PEST 3.0 Operating Manual. 1993;Reading University, Reading.
26. Marrugat J, Sala J, Masiá R. Mortality differences between men and women following first myocardial infarction. JAMA. 280:1998;1405-1409.